NCT02728895View on ClinicalTrials.gov

Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 15, 2016

Primary Completion Date

July 10, 2018

Study Completion Date

July 10, 2018

Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Vedolizumab

Vedolizumab Injection.

Trial Locations (5)

2215

Dana-Farber Cancer Institute, Boston

10029

Icahn School of Medicine at Mount Sinai, New York

43210

OSU - James Comprehensive Cancer Center, Columbus

53266

Medical College of Wisconsin, Inc., Milwaukee

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY